Novo Nordisk's Wegovy pill becomes the first FDA-approved oral GLP-1 weight-loss medication, launching January 2026 at $149/month as the Danish drugmaker aims to reclaim market share from Eli Lilly.
Amneal Pharmaceuticals and mAbxience announce FDA approval of Boncresa and Oziltus, biosimilar alternatives to Prolia and XGEVA for bone health treatment.
Nine pharmaceutical giants including Merck and GSK agree to slash U.S. drug prices to match other wealthy nations under new Trump administration deals, offering discounts up to 70%.
Leerink rates ImageneBio stock Outperform with $30 target, calling it "undervalued."
The Trump administration is working on "TrumpRx," a new site connecting consumers to drugmakers, pharmacies, and discount programs like GoodRx to help lower prescription costs.
Pfizer becomes the first pharmaceutical company to announce a drug-pricing deal with the Trump administration, promising lower prices for up to 100 million patients and committing $70 billion to domestic R&D and manufacturing.
